NBIXNeurocrine Biosciences, Inc.

Healthcare

$142.66+3.7% 1Y

$142.66

$123.1052 weeks$182.85

Is the business good?

Good

A genuinely good business: earnings fully cash-backed (1.5×) and margins widening.

2 good, 2 neutral

Fundamental health (F-score)5 / 9SEC EDGAR · Dec 31, 2025

Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.

Profits arrive as cash1.51×derived · Jun 30, 2026

Operating profit is fully backed by cash. Conversion is worsening vs a year ago.

Margin direction, 3 years+14.7 pts

Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.

Where ROE comes from12% ROA

Margin-driven, fat margins on slower asset turns. ROE 17% = margin × turnover × leverage.

Unless marked, from derived.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF conversionmiddle of the market

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

How good a business is NBIX?

Neurocrine Biosciences, Inc. keeps 24% of every revenue dollar as operating profit, against 9.5% for the median Drug Manufacturers - Specialty & Generic name.

24%

Operating margin · Drug Manufacturers - Specialty & Generic median 9.5% · 12 months to Q2 2026

Cash conversion: 1.51×
Cash conversion · 1.73× a year ago · operating cash flow covers the operating profit after tax
Share count, year on year: +3.2%
Share count, year on year · shareholders own a smaller slice than a year ago
R&D as % of revenue: 34%
R&D as % of revenue